Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
STEMLINE THERAPEUTICS INC (STML)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Mar-31-20 | Dec-31-19 | Sep-30-19 | Jun-30-19 | Mar-31-19 | Dec-31-18 | Sep-30-18 | Jun-30-18 |
| | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues: |
| United States | 7.3 | | | | 5.0 | | | |
| Other | 1.6 | | | | | | | |
| Revenues | 8.9 | 11.8 | 13.3 | 13.0 | 5.0 | 0.0 | 0.0 | 0.5 |
| Revenue growth [+] | 75.7% | | | 2501.3% | | | -100.0% | 67.0% |
| United States | 45.0% | | | | | | | |
| Cost of goods sold | 0.6 | 3.2 | 1.1 | 0.6 | 0.1 | 0.0 | 0.0 | 0.0 |
| Gross profit | 8.2 | 8.7 | 12.3 | 12.4 | 5.0 | 0.0 | 0.0 | 0.5 |
| Gross margin | 92.8% | 73.3% | 92.0% | 95.5% | 98.3% | | | 100.0% |
| Selling, general and administrative [+] | 18.5 | 16.5 | 15.4 | 19.0 | 16.0 | 14.9 | 9.6 | 8.6 |
| General and administrative | | 16.5 | | | | 14.9 | | |
| Other selling, general and administrative | | | | | | | | |
| Research and development | 11.5 | 10.5 | 12.3 | 10.9 | 17.0 | 12.1 | 11.8 | 11.2 |
| EBITDA [+] | -21.8 | -18.3 | -15.5 | -17.4 | -27.9 | -26.9 | -21.4 | -19.3 |
| EBITDA growth | -21.8% | -31.9% | -27.7% | -9.6% | 49.8% | 22.7% | 31.5% | 23.2% |
| EBITDA margin | -246.1% | -155.0% | -116.0% | -134.1% | -553.1% | | | -3858.9% |
| Depreciation and amortization | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT [+] | -21.9 | -18.3 | -15.5 | -17.5 | -27.9 | -26.9 | -21.4 | -19.3 |
| EBIT growth | -21.8% | -31.9% | -27.7% | -9.5% | 49.9% | 22.7% | 31.6% | 23.3% |
| EBIT margin | -246.3% | -155.1% | -116.1% | -134.3% | -553.5% | | | -3861.3% |
| Interest income, net [+] | 0.6 | 0.8 | 0.6 | 0.6 | 0.5 | 0.3 | 0.4 | 0.4 |
| Interest expense | 0.0 | 0.0 | | | 0.0 | 0.0 | | |
| Interest income | 0.6 | 0.8 | 0.6 | 0.6 | 0.5 | 0.3 | 0.4 | 0.4 |
| Other income (expense), net [+] | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | 0.0 |
| Other non-ooperating expenses | | | | 0.0 | | | | 0.0 |
| Other | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | | 0.0 |
| Pre-tax income | -21.3 | -17.6 | -14.9 | -16.9 | -27.4 | -26.6 | -21.0 | -18.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -21.3 | -17.7 | -14.9 | -16.8 | -27.4 | -26.6 | -21.0 | -18.9 |
| Net margin | -240.0% | -149.5% | -111.7% | -129.5% | -542.9% | | | -3785.7% |
| |
| Basic EPS [+] | ($0.45) | ($0.42) | ($0.34) | ($0.42) | ($0.73) | ($0.94) | ($0.73) | ($0.66) |
| Growth | -38.8% | -55.2% | -53.1% | -36.6% | 6.4% | -0.5% | 6.0% | 0.4% |
| Diluted EPS [+] | ($0.45) | ($0.42) | ($0.34) | ($0.42) | ($0.73) | ($0.94) | ($0.73) | ($0.66) |
| Growth | -38.8% | -55.2% | -53.1% | -36.6% | 6.4% | -0.5% | 6.0% | 0.4% |
| |
| Shares outstanding (basic) [+] | 47.7 | 42.1 | 43.7 | 40.1 | 37.6 | 28.4 | 29.0 | 28.6 |
| Growth | 27.0% | 48.3% | 50.7% | 40.4% | 39.9% | 23.1% | 23.7% | 22.0% |
| Shares outstanding (diluted) [+] | 47.7 | 42.1 | 43.7 | 40.1 | 37.6 | 28.4 | 29.0 | 28.6 |
| Growth | 27.0% | 48.3% | 50.7% | 40.4% | 39.9% | 23.1% | 23.7% | 22.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|